Low Dose Daily Erlotinib in Combination With High Dose Twice Weekly Erlotinib in Patients With EGFR-Mutant Lung Cancer

Clinical trial NCT01967095 · COMPLETED

Trial details

NCT number: NCT01967095
Sponsor: Memorial Sloan Kettering Cancer Center
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

EGFR-Mutant Lung Cancer

Start date: 2013-10-15
Primary completion: 2018-11-08
Enrollment: 53

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.